U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06796998) titled 'Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)' on Jan. 22.
Brief Summary: The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).
Study Start Date: May 01, 2025
Study Type: INTERVENTIONAL
Condition:
Marginal Zone Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Splenic Marginal Zone Lymphoma
Nodal Marginal Zone Lymphoma
Intervention:
BIOLOGICAL: Epcoritamab
Epcoritamab will be administered via subcutaneous (SC) injection using a step-up dosing schedule as follows:
* Cycle...